Data on sprytne.com is aggregated from official U.S. Government sources including the SEC EDGAR database, USAspending.gov, USPTO, and U.S. Census Bureau. In accordance with 17 U.S.C. § 105, works of the U.S. Government are not subject to copyright protection and reside in the Public Domain. sprytne.com provides value-added visualization and algorithmic analysis of these public records.
Not financial advice. sprytne.com is an automated market intelligence platform. We are not a registered investment advisor, broker, or dealer. Financial metrics, risk scores, and federal award data are for informational purposes only. Past performance (including government contract history) is not indicative of future market results. Verify all data via official SEC.gov filings.
This platform adheres to CCPA/GDPR standards regarding professional and public business data. Information displayed pertains to commercial entities and public officers in their professional capacity. For data verification or removal requests regarding non-public information, please visit our Contact page. Operated under Brand House Data Systems framework.
© 2026 sprytne.com — Institutional Data Intelligence — Federal Transparency Initiative
Ticker HOLX · Nasdaq · DE
HOLOGIC INC is a U.S. business entity operating within the X-Ray Apparatus & Tubes sector (SIC 3844). Publicly traded on the Nasdaq under the ticker symbol HOLX, the company is incorporated in Delaware. Based on SEC EDGAR filings, HOLX reported fiscal year 2025 revenue of $4.10B, reflecting a year-over-year growth of 1.7%. Our proprietary Semantic Risk Score of 14 indicates high transparency and low reporting risk, derived from the frequency and consistency of 10-K, 10-Q, and 8-K filing patterns. As part of the SIC 3844 classification, HOLOGIC INC serves as a key benchmark for investors and analysts monitoring Delaware corporate performance.
Comparison based on Standard Industrial Classification (SIC) mapping from SEC EDGAR filings.
Filing data sourced from SEC EDGAR signals. 10-K = annual report · 10-Q = quarterly · 8-K = material event.
HOLOGIC INC (HOLX) — Key efficiency & solvency metrics · FY2025
Operating Margin
Sector avg: -19.24%
Net Margin
Sector avg: -18.35%
Debt-to-Equity
Sector avg: 1.61
Current Ratio
Sector avg: 2.98
| Key Metric | Company | Industry Avg | Status |
|---|---|---|---|
| Total RevenueYoY: +1.7% | $4.10B | $8.27B | ▼ Lagging |
| Net IncomeYoY: -28.3% | $565.7M | — | — |
| Operating MarginOperating income as % of revenue | 17.4% | -19.24% | ▲ Outperform |
| Net MarginNet income as % of revenue | 13.8% | -18.35% | ▲ Outperform |
| Debt-to-EquityTotal liabilities / stockholders equity. Lower = safer. | 1.79 | 1.61 | ▼ Leveraged |
| Current RatioCurrent assets / current liabilities. Above 1.0 = solvent. | 3.75 | 2.98 | ▲ Outperform |
Source: SEC EDGAR XBRL filings (10-K annual reports). Industry benchmarks derived from 3 companies in SIC 3844.
Disclaimer: All financial data is sourced from raw SEC EDGAR filings. Sprytne.com provides automated data visualization and algorithmic analysis for informational purposes only. This is NOT financial advice, a recommendation to buy/sell, or a guarantee of accuracy. Always verify data via official SEC sources before making investment decisions.
Federal Contracts
COVID-19 DHHS HOLOGIC, INC. PRODUCTION CAPACITY EXPANSION -- ACTION AWARDED UNDER CSO FA7013-20-S-0002
THE PURPOSE IS TO ENSURE TEST AVAILABILITY FOR SARS-COV-2 AFTER THE EMERGENCY AUTHORIZATION CLOSES BY SUBMITTING AN IN VITRO DIAGNOSTIC OR IVD ASSAY FOR SARS-COV-2, INFLUENZA (FLU) A, FLU B AND RESPIRATORY SYNCYTIAL VIRUS (RSV) ALONG WITH A RESPIRATO
ASPR-21-00523 -- BASE PERIOD FUNDS TO HOLOGIC INC RESPIRATORY PANEL (SARS-COV FLUA FLUB RSV) FOR USE ON THE HOLOGIC PANTHER FUSION SYSTEM
APTIMA SARS-COV-2 TESTS ON HOLOGIC PANTHER SYSTEMS
COVID-19 DHHS HOLOGIC EXPANSION PROJECT
HIGH TECH BIO-MEDICAL EQUIPMENT AND ACCESSORIES
EXPANDING PRODUCTION CAPACITY FOR THE PANTHER FUSION SARS-COV-2 ASSAY
CT/GC TEST REAGENTS BASE YEAR
ANALYZERS, LAB, MOLECULAR ASSAY (PANTHER) - NMC PORTSMOUTH, VA
IGF::OT::IGF HOLOGIC - THE BASE PERIOD OF THE CONTRACT WILL SUPPORT DEVELOPMENT OF A BLOOD-SCREENING ASSAY FOR THE DETECTION OF ZIKV RNA IN PLASMA SAMPLES FROM WHOLE BLOOD DONORS.
Source: USAspending.gov (Official Federal Award Data). Reflects prime contracts only. Last sync: 2026-03-30.
Compared to 6 peers in X-Ray Apparatus & Tubes (SIC 3844)
Revenue
Net Margin
SEC EDGAR XBRL filings by fiscal year
Side-by-side financial showdown — revenue, margins, and growth.
Methodology & compliance note
Data is aggregated from SEC EDGAR and Secretary of State public records. Any analytics such as "market share" are statistical estimates (proxy models) and are not official audits, valuations, or investment advice. Sprytne.com is an independent data aggregator and is not affiliated with any government agency.Learn more →